It shortens bleeding time and improves hemostasis by increasing VWF and factor VIII levels, making it an attractive potential therapy for the acquired VWF deficiency implicated in LVAD-related GIB. The gene discussed is VWF; the disease is hyperinsulinemic hypoglycemia, familial, 4.